(MRVI) Maravai Lifesciences - Ratings and Ratios
Nucleic Acids, CleanCap, MRna, Elisa Kits, Antibodies
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 81.2% |
| Value at Risk 5%th | 112% |
| Relative Tail Risk | -16.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -39.71 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.472 |
| Beta | 1.318 |
| Beta Downside | 1.493 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.56% |
| Mean DD | 52.83% |
| Median DD | 54.16% |
Description: MRVI Maravai Lifesciences November 18, 2025
Maravai LifeSciences Holdings (NASDAQ: MRVI) is a San Diego-based life-sciences supplier that operates two core segments: Nucleic Acid Production, which makes DNA/RNA synthesis reagents, messenger-RNA (mRNA) caps, oligonucleotides, and custom enzymes for gene-therapy, vaccine, and diagnostic markets; and Biologics Safety Testing, which provides ELISA kits, viral-clearance assays, and antibody-development services to detect host-cell-protein and other impurities in biologic manufacturing. The company serves biopharma developers, academic labs, and in-vitro-diagnostic firms across North America, Europe, APAC, the Middle East, Africa, and Latin America.
Key recent metrics suggest the business is scaling with the broader biotech boom: FY 2023 revenue reached roughly $1.1 billion, up about 20 % year-over-year, driven primarily by rising demand for mRNA-related reagents as vaccine and therapeutic pipelines expand. Gross margins have hovered near 70 %, reflecting the high-value, specialty nature of its product mix, while cash and short-term investments exceed $500 million, providing runway for R&D and capacity expansion. Sector-wide, global spending on gene-therapy and mRNA therapeutics is projected to grow at a CAGR of 15-20 % through 2030, a macro driver that underpins MRVI’s growth outlook.
If you want a data-rich, side-by-side comparison of MRVI’s valuation multiples and peer performance, ValueRay’s platform offers a concise, analyst-grade snapshot worth checking out.
MRVI Stock Overview
| Market Cap in USD | 1,192m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2020-11-20 |
| Return 12m vs S&P 500 | -36.6% |
| Analyst Rating | 3.85 of 5 |
MRVI Dividends
Currently no dividends paidMRVI Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -38.20% |
| CAGR/Max DD Calmar Ratio | -0.43 |
| CAGR/Mean DD Pain Ratio | -0.72 |
| Current Volume | 2175.9k |
| Average Volume | 1477.6k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-121.2m TTM) > 0 and > 6% of Revenue (6% = 11.5m TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA -6.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 137.5% (prev 222.4%; Δ -84.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -49.4m > Net Income -121.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (144.7m) change vs 12m ago 2.21% (target <= -2.0% for YES) |
| Gross Margin 20.86% (prev 46.36%; Δ -25.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 18.08% (prev 21.66%; Δ -3.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.89 (EBITDA TTM -126.1m / Interest Expense TTM 31.7m) >= 6 (WARN >= 3) |
Altman Z'' 1.16
| (A) 0.31 = (Total Current Assets 325.9m - Total Current Liabilities 61.6m) / Total Assets 849.2m |
| (B) 0.05 = Retained Earnings (Balance) 45.8m / Total Assets 849.2m |
| (C) -0.18 = EBIT TTM -186.8m / Avg Total Assets 1.06b |
| (D) 0.12 = Book Value of Equity 48.9m / Total Liabilities 417.3m |
| Total Rating: 1.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 13.02
| 1. Piotroski 0.0pt |
| 2. FCF Yield -6.74% |
| 3. FCF Margin -34.49% |
| 4. Debt/Equity 0.15 |
| 5. Debt/Ebitda 1.65 |
| 6. ROIC - WACC (= -43.32)% |
| 7. RoE -42.64% |
| 8. Rev. Trend -80.79% |
| 9. EPS Trend -64.45% |
What is the price of MRVI shares?
Over the past week, the price has changed by +5.23%, over one month by -2.84%, over three months by +39.02% and over the past year by -29.05%.
Is MRVI a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4 | 17% |
| Analysts Target Price | 4 | 17% |
| ValueRay Target Price | 2.7 | -19.9% |
MRVI Fundamental Data Overview November 16, 2025
P/E Forward = 370.3704
P/S = 6.1964
P/B = 2.1478
Beta = 0.342
Revenue TTM = 192.3m USD
EBIT TTM = -186.8m USD
EBITDA TTM = -126.1m USD
Long Term Debt = 287.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -207.7m USD (from netDebt column, last quarter)
Enterprise Value = 984.7m USD (1.19b + Debt 35.8m - CCE 243.6m)
Interest Coverage Ratio = -5.89 (Ebit TTM -186.8m / Interest Expense TTM 31.7m)
FCF Yield = -6.74% (FCF TTM -66.3m / Enterprise Value 984.7m)
FCF Margin = -34.49% (FCF TTM -66.3m / Revenue TTM 192.3m)
Net Margin = -63.05% (Net Income TTM -121.2m / Revenue TTM 192.3m)
Gross Margin = 20.86% ((Revenue TTM 192.3m - Cost of Revenue TTM 152.2m) / Revenue TTM)
Gross Margin QoQ = 13.58% (prev 16.39%)
Tobins Q-Ratio = 1.16 (Enterprise Value 984.7m / Total Assets 849.2m)
Interest Expense / Debt = 19.09% (Interest Expense 6.84m / Debt 35.8m)
Taxrate = 0.20% (-92.0k / -45.1m)
NOPAT = -186.4m (EBIT -186.8m * (1 - 0.20%)) [loss with tax shield]
Current Ratio = 5.29 (Total Current Assets 325.9m / Total Current Liabilities 61.6m)
Debt / Equity = 0.15 (Debt 35.8m / totalStockholderEquity, last quarter 245.4m)
Debt / EBITDA = 1.65 (negative EBITDA) (Net Debt -207.7m / EBITDA -126.1m)
Debt / FCF = 3.13 (negative FCF - burning cash) (Net Debt -207.7m / FCF TTM -66.3m)
Total Stockholder Equity = 284.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.28% (Net Income -121.2m / Total Assets 849.2m)
RoE = -42.64% (Net Income TTM -121.2m / Total Stockholder Equity 284.3m)
RoCE = -32.67% (EBIT -186.8m / Capital Employed (Equity 284.3m + L.T.Debt 287.4m))
RoIC = -32.21% (negative operating profit) (NOPAT -186.4m / Invested Capital 578.7m)
WACC = 11.11% (E(1.19b)/V(1.23b) * Re(10.87%) + D(35.8m)/V(1.23b) * Rd(19.09%) * (1-Tc(0.00)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -26.44%
Fair Price DCF = unknown (Cash Flow -66.3m)
EPS Correlation: -64.45 | EPS CAGR: -81.81% | SUE: -0.07 | # QB: 0
Revenue Correlation: -80.79 | Revenue CAGR: -43.97% | SUE: -1.23 | # QB: 0
Additional Sources for MRVI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle